BiotechTube
Salubris Biotherapeutics

Salubris Biotherapeutics

Gaithersburg, United States· Est.
salubrisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $70M

Overview

Salubris Biotherapeutics is a private, clinical-stage biotech founded in 2015 and headquartered in Gaithersburg, Maryland. The company is developing novel antibody-based therapeutics targeting the two leading global causes of death: cardiovascular disease and cancer. Led by a seasoned team of industry veterans, SalubrisBio leverages its expertise in complex biologics to advance its pipeline through clinical development. The company is currently pre-revenue and focused on progressing its research programs.

Cardiovascular DiseaseOncology

Technology Platform

Expertise in developing novel antibody and protein-based complex biologics for cardiovascular and oncology indications.

Funding History

2
Total raised:$70M
Series B$50M
Series A$20M

Opportunities

The company targets two of the largest and most persistent therapeutic markets globally: cardiovascular disease and oncology.
Developing first-in-class biologics in these areas offers the potential for high-impact therapies and significant commercial value if clinical success is achieved.
An experienced leadership team with strong commercial and development backgrounds positions the company well for strategic partnerships and value creation.

Risk Factors

The company faces high clinical development risk, as its novel biologics may fail in trials.
As a private, pre-revenue firm, it is dependent on securing external financing to fund operations and costly clinical studies.
It also operates in intensely competitive landscapes against large, well-resourced pharmaceutical companies.

Competitive Landscape

The cardiovascular and oncology therapeutic areas are among the most competitive in biopharma, dominated by large-cap companies and numerous innovative biotechs. SalubrisBio will need to demonstrate clear differentiation through novel mechanisms of action or superior clinical profiles to capture market share. Its focus on complex biologics places it against other antibody-focused developers and potentially newer modality companies.

More companies in United States →